Reviewed by Peptide Treatments Medical Advisory Board
Survodutide: Side Effects & Safety
Known side effects, safety considerations, and adverse reaction data for Survodutide.
Back to Survodutide overviewData source: Side effect data comes from clinical trials, preclinical research, and anecdotal reports. No FDA-approved labeling exists for this compound.
Reported Side Effects (8 items)
| # | Side Effect |
|---|---|
| 1 | Nausea (45-58%) — notably higher than GLP-1 monotherapy due to glucagon component |
| 2 | Diarrhea (22-30%) |
| 3 | Vomiting (18-25%) |
| 4 | Constipation (15-18%) |
| 5 | Injection site reactions (8-12%) |
| 6 | Gallbladder disease (1.2%, higher than GLP-1 monotherapy) |
| 7 | Pancreatitis (0.3-0.5%) |
| 8 | Hypoglycemia (2-3%, primarily with co-administered insulin/secretagogues) |
Known Drug Interactions
Important: Only documented and contraindicated interactions are shown here. View all interactions including theoretical →
| Drug | Classification | Mechanism |
|---|---|---|
| oral contraceptives | Documented | Delayed gastric emptying may reduce oral contraceptive efficacy — use backup contraception |
| insulin and sulfonylureas | Documented | Additive glucose-lowering increases hypoglycemia risk — reduce sulfonylurea dose by 50% |
| other GLP-1 receptor agonists | Documented | Duplicative GLP-1 signaling with no added benefit — do not combine |